Entered into a definitive merger agreement with Advaxis Inc. – transaction expected to close by end of Q1 2023, subject to approval by Ayala’s shareholders.
– Presented Positive Data from Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Progressing Desmoid Tumors at the European Society for.
Ayala Pharmaceuticals to Host Key Opinion Leader Webinar on Desmoid Tumors - read this article along with other careers information, tips and advice on BioSpace
Ayala Pharmaceuticals to Host Key Opinion Leader Webinar on Desmoid Tumors streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Significant improvement in progression-free survival and response rate combined with reduced symptoms and better quality of life are reported as outcomes of a new treatment approach for patients with desmoid tumors, which are benign, but locally aggressive and invasive soft tissue tumors.